Literature DB >> 18365885

Design and synthesis of novel galactosylated polymers for liposomes as gene drug carriers targeting the hepatic asialoglycoprotein receptor.

Si Ling Wang1, Feng Bo Yu, Tong Ying Jiang, Chang Shan Sun, Tianyi Wang, Jing Hai Zhang.   

Abstract

The 18-mer oligodeoxynucleotides (ODNs) that can inhibit survivin gene expression were selected as a model gene drug to study hepatic-targeting drug delivery system. Novel galactosylated polymers (cholesteryloxycarbonylamino) ethylamine-alpha,beta-polyasparthydrazied (CHE-PAHy-Lacs), which target asialoglycoprotein receptor on hepatic parenchymal cells (PC), were designed and synthesized as non-toxic, non-antigenic and non-teratogenic ligands for liposomes. The liposomes incorporating different CHE-PAHy-Lacs were prepared and characterized by zeta potential and particle size analyzer. The drug encapsulation efficiency was measured by gel filtration method. 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate was used as a marker for all the liposome preparations in the in vivo experiments. The CHE-PAHy-Lac liposomes produced a significant improvement in the encapsulation efficiency of ODNs (28.73-51.37%) compared with conventional liposomes (9.88%). The in vivo results showed that the liposomes incorporating CHE-PAHy-Lac, which contained about 30% (w/w) galactosyl residues, exhibited marked accumulation in the liver and hepatic PC. These results suggest that the novel galactosylated polymers used for liposomes have a great potential as a gene delivery system for hepatic targeting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18365885     DOI: 10.1080/10611860801902609

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

1.  Rational design, fabrication, characterization and in vitro testing of biodegradable microparticles that generate targeted and sustained transgene expression in HepG2 liver cells.

Authors:  Janjira Intra; Aliasger K Salem
Journal:  J Drug Target       Date:  2010-08-03       Impact factor: 5.016

2.  Modifying glycyrrhetinic acid liposomes with liver-targeting ligand of galactosylated derivative: preparation and evaluations.

Authors:  Jing Chen; Yuchao Chen; Yi Cheng; Youheng Gao; Pinjing Zheng; Chuangnan Li; Yidan Tong; Zhao Li; Wenhui Luo; Zhao Chen
Journal:  Oncotarget       Date:  2017-10-27

3.  Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis.

Authors:  Anurag Mishra; Tamara R Castañeda; Erik Bader; Bettina Elshorst; Sheila Cummings; Petra Scherer; Dinesh S Bangari; Claudia Loewe; Herman Schreuder; Christoph Pöverlein; Mike Helms; Seth Jones; Gernot Zech; Thomas Licher; Michael Wagner; Manfred Schudok; Meltsje de Hoop; Alleyn T Plowright; Jens Atzrodt; Aimo Kannt; Iina Laitinen; Volker Derdau
Journal:  Adv Sci (Weinh)       Date:  2020-11-09       Impact factor: 16.806

4.  5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.

Authors:  Mingrong Cheng; Bing He; Tao Wan; Weiping Zhu; Jiang Han; Bingbing Zha; Houxiang Chen; Fengxiao Yang; Qing Li; Wei Wang; Hongzhi Xu; Tao Ye
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

5.  Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.

Authors:  Chen Zhao; Qiang Feng; Zengpei Dou; Wei Yuan; Chenguang Sui; Xinghua Zhang; Guimin Xia; Hongfang Sun; Jie Ma
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.